Skip to main content
. 2024 May 7;11(6):1442–1455. doi: 10.1002/acn3.52056

Figure 1.

Figure 1

Long‐term effects of ALEM on the annualized relapse rate (ARR) and on the EDSS. (A, B) ARR among the whole cohort. (C, D) ARR among patients with ongoing relapse activity throughout the observation period. (E) Median EDSS scores at baseline (BL) and at the last available follow‐up; (A, C) data are shown as means with 95% CI; (E) The BL EDSS refers to the EDSS at 30 days from ALEM start. ALEM, alemtuzumab; BL, baseline; CI, confidence interval; EDSS, Expanded Disability Status Scale.